Previous 10 | Next 10 |
MALVERN, Pa., April 20, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that the Company will present on its innova...
2023-04-19 10:32:41 ET If you’re looking for penny stocks to buy now, there’s a lot to account for in the stock market today. Whether it’s the overarching recession and inflation story or the underpinnings of a potential stock market crash in 2023, emotions are ridi...
2023-04-14 11:10:07 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Getty Images (NYSE: GETY ) stock is on the rise Friday as investors take note of Trillium Capital seeking a seat on the company’s board of directors. Trillium...
2023-04-14 10:48:46 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips SoFi Technologies (NASDAQ: SOFI ) stock is on the rise Friday as the company’s shares rally alongside other shares in the financial sector. Bank stocks are gett...
2023-04-14 10:33:17 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Bank stocks are on the move Friday after several companies in the sector released their earnings reports today. Starting off with JPMorgan Chase (NYSE: JPM ), the compan...
2023-04-14 10:00:24 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Ocugen (NASDAQ: OCGN ) stock is on the move Friday after the company revealed preliminary results from an ongoing clinical trial . The preliminary results come from the ...
2023-04-14 08:29:09 ET Ocugen ( NASDAQ: OCGN ) shares gained 6% premarket on Friday after the biotechnology company reported positive prelim results from a Phase 1/2 Trial of its modifier gene therapy candidate, OCU400. OCU400 is a gene therapy being developed by Ocuge...
Favorable safety and tolerability profile related to OCU400 investigational product candidate Initial clinical data from low and medium dose cohorts indicates positive trend in Multi-luminance mobility testing and Best-Corrected Visual Acuity scores for OCU400 treated eyes 71.4%...
MALVERN, Pa., April 11, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that it will host an Investor and Analyst E...
MALVERN, Pa., March 31, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that the Company’s Chief Scientific ...
News, Short Squeeze, Breakout and More Instantly...
• Initiated Phase 2 clinical trial MALVERN, Pa., July 25, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and va...
2024-07-11 08:45:00 ET It hasn't been a stellar year so far for biotech companies. The industry, as measured by the SPDR S&P Biotech ETF , is up just 4% since January, significantly lagging the S&P 500 's nearly 17% gain. Of course, it's not hard to find stocks that have...